Home | Login
MASC - Melanoma and Skin Cancer Trials

Melanoma and Skin Cancer Trials




Please enter your username and password.




Current Trials

01.07 - WBRTMel Trial

This international, randomized, phase III trial will determine if the addition of whole brain radiotherapy after surgery or local stereotactic radiotherapy improves the control of melanoma metastases in the brain, neurocognitive function, survival and quality of life.

01.09 RTN2 Trial - A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision

Neurotropism, defined as invasion by melanoma of peripheral neural tissue, is uncommon but it is this feature which is linked with a high risk of the cancer coming back in the same area. The primary aim of this trial is to determine if there is a difference in the rate of relapse between 2 randomised groups of patients treated after surgery with either radiation therapy or initial observation.

01.10 - CARPETS

Oral kinase inhibitors are proving to be effective in up to 60% of malignant melanomas that are found to have a BRAF mutation. However, drug resistance is emerging and many patients relapse affirming the need for further treatment development. This Phase I study is assessing the safety and immune effects of using autologous peripheral blood T cells in GD2 positive patients being treated with vemurafenib.

01.12 EAGLE FM Trial - Inguinal or Ilio-inguinal Lymphadenectomy for patients with metastatic melanoma to groin lymph nodes and no evidence of pelvic disease on PET/CT Scan - A randomised phase III trial

Spread of metastatic melanoma to the groin lymph nodes is a common event for patients with melanoma. In melanoma treatment centres around the world, management of patients with clear pelvic lymph node disease vary. Thismulti-centre, phase III, prospective, randomised clinical trial aims to assess the effectiveness and morbidity of Complete Inguinal Lymphadenectomy versus Complete Ilio-ingional Lymphadenectomy for patients with metastatic melanoma and negative pelvic staging on PET / CT scan

02.12 RADICAL Trial - A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna (LM) when staged surgical excision with 5mm margins is not possible, is refused, or fails

To date, there have been no prospective studies or randomised controlled trials (RCT) conducted to form the basis of any recommendations for the management of Lentigo Maligna. In order to establish the optimum management for these patients and to accurately evaluatethese treatments a prospective randomised controlled clinical trial is required.

02.18 MelMarT-II Trial- A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma

Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with a primary invasive cutaneous melanomas >=1mm thick to determine differences in the rate of local recurrence and melanoma specific survival. A reduction in margins is expected to improve quality of life in patients.

02.14 CombiRT Trial - An open-label, single-arm, phase I/II, multicenter study to evaluate safety and efficacy of combination of dabrafenib, trametinib and palliative radiotherapy in metastatic BRAF mutation positive cutaneous melanoma

An open-label, single-arm, phase I/II, multicenter study to evaluate the safety and efficacy of the combination of dabrafenib, trametinib and palliative radiotherapy in patients with inoperable (stage IIIc) and metastatic (stage IV) BRAF V600E/K mutation-positive cutaneous melanoma.

01.15 CHARLI Trial - An open-labelled, non-comparative, multisite, two arm Phase Ib/II study investigating checkpoint and RANK-Ligand inhibition

A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV Melanoma  

02.17 MEL-SELF Trial - Can patient-led surveillance detect more early stage recurrent or new primary melanoma than clinician-led surveillance?

An increasing number of patients in Australia require lifelong follow-up after treatment for localised melanoma, and dermatology and skin cancer clinics are struggling with this demand. An alternative model of to the traditional 'clinician-led' surveillance is 'patient-led' surveillance: combination of smartphone supported self-examination, teledermatology and patient initiated clinic visits when needed.

02.18 MelMarT-II Trial

02.18 MelMarT-II Trial

Return to Trials main page.